| Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 10535387 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Several mechanisms other than the inhibition of systemic and local formation of angiotensin II (Ang II) have been proposed to play a role in mediating the hypotensive effects of angiotensin-converting enzyme (ACE) inhibitors. In the present study, we measured plasma levels of nitric oxide (NO) and the related vasoactive factors bradykinin, 6-keto prostaglandin F1alpha (6-keto PGF1alpha) a stable metabolite of prostacyclin, and cyclic guanosine-3',5'-monophosphate (cGMP) before and after a 4-week treatment with the ACE inhibitor lisinopril in 17 patients with essential hypertension. Plasma NO levels were measured by the Griess method after conversion of nitrate to nitrite. Long-term lisinopril treatment significantly reduced blood pressure and increased plasma NO and 6-keto PGF1alpha. The treatment also tended to increase plasma levels of bradykinin and cGMP, but not to a significant extent. The posttreatment NO level was inversely correlated with posttreatment systolic, diastolic, and mean blood pressure (n = 17, r= -.68, P< .01, n = 17, r= -.54, P < .05, and n = 17, r= -.66, P< .01, respectively). The posttreatment bradykinin level was also modestly correlated with posttreatment systolic and mean blood pressure (n = 17, r = -.51, P < .05 and n = 17, r = -.55, P < .05, respectively). In contrast, posttreatment 6-keto PGF1alpha and cGMP levels were not correlated with posttreatment systolic, diastolic, or mean blood pressure. These findings raise the possibility that increased formation of NO and bradykinin, as well as inhibition of the renin-angiotensin system, contribute to the hypotensive effect of the ACE inhibitor observed in our hypertensive patients. |
| | |
Authors:
|
M Kohno; K Yokokawa; M Minami; K Yasunari; K Maeda; H Kano; T Hanehira; J Yoshikawa |
Related Documents
:
|
12753417 - Hypertension due to blockade of adenosine receptors. 8576937 - Effects of long-term therapy with ace inhibitors, captopril, enalapril and trandolapril... 15889697 - Partial angiotensin-converting enzyme inhibition during acute orthostatic stress in per... 11229627 - Beneficial effect of verapamil added to chronic ace inhibitor treatment on renal functi... 6840917 - Assessment of ventricular function by combined noninvasive measures: factors accounting... 8779757 - Pressure control for complete denture impressions. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 48 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 1999 Oct |
Date Detail:
|
Created Date: 1999-11-05 Completed Date: 1999-11-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1256-9 Citation Subset: IM |
Affiliation:
|
First Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
6-Ketoprostaglandin F1 alpha
/
blood Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Blood Pressure / drug effects* Blood Urea Nitrogen Bradykinin / blood* Cyclic GMP / blood Diastole / drug effects Female Humans Hypertension / blood*, drug therapy*, physiopathology Male Middle Aged Nitric Oxide / blood* Pulse Regression Analysis Renin / blood Systole / drug effects Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 10102-43-9/Nitric Oxide; 58-82-2/Bradykinin; 58962-34-8/6-Ketoprostaglandin F1 alpha; 7665-99-8/Cyclic GMP; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing sig...
Next Document: Hepatic nonoxidative disposal of an oral glucose meal in patients with liver cirrhosis.